Allosteric screening and synthetic lethality platforms with 200k library.
Competing Products
Allorion Therapeutics
Allorion Therapeutics: Developing small molecule drugs for cancer and autoimmune diseases globally.
Founded
2020Allorion Therapeutics: Developing small molecule drugs for cancer and autoimmune diseases globally.
Founded with a mission to develop next-generation targeted drugs, Allorion Therapeutics focuses on creating small molecule therapeutics for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company leverages innovative discovery platforms and a robust R&D team to address unmet patient needs. Allorion's science- and data-driven approach aims to produce globally competitive drugs, and it seeks to enhance commercialization through partnerships with leading pharmaceutical companies.
Notable figures affiliated with Allorion Therapeutics include esteemed scientists and industry experts who drive its innovative research and development efforts. The company has garnered attention for its promising drug pipeline and strategic collaborations. By advancing precision medicine, Allorion has made significant strides in improving treatment options for complex diseases, thereby impacting global healthcare positively.
Companies similar to Allorion Therapeutics include Jacobio Pharma, Gain Therapeutics, Tango Therapeutics and Incyte.
Allorion Therapeutics was founded in 2020.
Allorion Therapeutics' headquarters is located in Natick, MA, US.
Allorion Therapeutics' most recent funding round was for $50M (USD) in March 2023.
As of Mar 9, 2023, Allorion Therapeutics has disclosed funding of $90M (USD). Undisclosed round amounts are excluded.
Allorion Therapeutics has 27 employees as of Feb 4, 2024.
Incyte
incyte.com
